Europe:+32-2-535-7543
Asia: +65-6223-2436
Int'l: +1-860-674-8796
US: +1-866-353-3335
  • Japanese
  • Korean
  • Chinese
Cover Image

China Blood Product Industry Report, 2015-2018

Recombinant blood products have developed for many years in foreign countries, but China's blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources are the key to the development of Chinese blood product enterprises.

Amid the industrial prosperity and favorable policies, China's production-use plasma volume broke through 4,000 tons and the total lot release volume jumped by 15% year on year to 52.4 million bottles in 2014. By lot release volume, human albumin, human rabies immunoglobulin, human immunoglobulin (ph4) for intravenous injection and tetanus immunoglobulin were the most popular blood products in China in 2014, accounting for 59.8%, 14.6%, 13.6% and 4.1% of the total lot release volume respectively.

At the same time, the supply and R & D capabilities of human blood coagulation factor VIII, human prothrombin complex and other small products in rigid demand have been intensified in recent years. In 2014, the lot release volume of the above two products ascended by 43.9% and 46.3% year on year respectively. Chengdu Rongsheng, Guangdong Danxia, Yuanda Shuyang, Shanxi Kangbao and other enterprises obtained clinical approval for their human blood coagulation factor VIII in 2014.

Given stringent requirements on new domestic plasma stations, Shanghai RAAS, China Biologic Products (Shandong Taibang and Guizhou Taibang), Hualan Biological Engineering, Tiantan Biological (including Chengdu Rongsheng) and Yuanda Shuyang which boast abundant capital, powerful R&D strength and rich plasma station resources have become the top five companies in China blood product industry, contributing 61.3% to China's production-use plasma volume and 33.6% to China's blood product revenue in 2014.

Shanghai RAAS turns to be a Chinese blood product leader through two acquisitions. In 2014, it took over Banghe Pharmaceutical (now known as Zhengzhou RAAS) and TONROL for RMB1.8 billion and RMB4.758 billion separately, so that the blood product varieties of the company increased from 7 to 11, the number of plasma collection stations rose from 12 to 28, and its plasma collection capacity expanded from 400 tons to 900 tons.

image1

China Blood Product Industry Report, 2015-2018 focuses on the followings:

  • Market characteristics, operating environments, status quo, etc. of China blood product industry;
  • Supply and demand, competitive landscape, import & export, development forecast, etc. of China blood product industry;
  • Supply and demand, competitive landscape, etc. of 8 blood product segments, including human albumin, human immunoglobulin (pH4) for intravenous injection, blood coagulation factor and tetanus human immunoglobulin.
  • Operation, blood product business and development prospects of 12 major Chinese blood product companies.

Table of Contents

1. Overview of Blood Product Industry

  • 1.1 Definition
  • 1.2 Classification
  • 1.3 Recombinant Blood Products
  • 1.4 Industry Chain
  • 1.5 Features

2. Overview of China Blood Product Industry

  • 2.1 Market Size
  • 2.2 Status Quo
  • 2.3 Supply and Demand
    • 2.3.1 Supply
    • 2.3.2 Demand
  • 2.4 Market Competition
  • 2.5 Operating Environment
    • 2.5.1 International Market
    • 2.5.2 Policy
    • 2.5.3 Domestic Biopharmaceutical Market
  • 2.6 Import and Export

3. Blood Product Market Segments in China

  • 3.1 Human Albumin
    • 3.1.1 Supply and Demand
    • 3.1.2 Competitive Landscape
    • 3.1.3 Development Prospect
  • 3.2 Human Immunoglobulin (pH4) for Intravenous Injection
    • 3.2.1 Supply and Demand
    • 3.2.2Competitive Landscape
  • 3.3 Blood Coagulation Factor VIII
    • 3.3.1 Supply and Demand
    • 3.3.2 Competitive Landscape
    • 3.3.3 Development Prospect
  • 3.4 Hepatitis B Immunoglobulin
    • 3.4.1 Supply and Demand
    • 3.4.2Competitive Landscape
  • 3.5 Human Immunoglobulin
    • 3.5.1 Supply and Demand
    • 3.5.2 Competitive Landscape
  • 3.6 Human Prothrombin Complex
    • 3.6.1 Supply and Demand
    • 3.6.2 Competitive Landscape
  • 3.7 Tetanus Immunoglobulin
    • 3.7.1 Supply and Demand
    • 3.7.2Competitive Landscape
  • 3.8 Human Rabies Immunoglobulin
    • 3.8.1 Supply and Demand
    • 3.8.2 Competitive Landscape

4. Major Chinese Manufacturers

  • 4.1 China Biologic Products Inc. (NASDAQ: CBPO)
    • 4.1.1 Profile
    • 4.1.2 Operation
    • 4.1.3 Revenue Structure
    • 4.1.4 Customers and Suppliers
    • 4.1.5 R & D and Investment
    • 4.1.6 Shandong Taibang Biological Products Co., Ltd.
    • 4.1.7 Guizhou Taibang Biological Products Co., Ltd.
    • 4.1.8 Xi'an Huitian Blood Products Co., Ltd.
    • 4.1.9 Prospect and Forecast
  • 4.2 Hualan Biological Engineering Inc. (002007.SZ)
    • 4.2.1 Profile
    • 4.2.2 Operation
    • 4.2.3 Revenue Structure
    • 4.2.4 Gross Margin
    • 4.2.5 Customers and Suppliers
    • 4.2.6 R & D and Investment
    • 4.2.7 Blood Products
    • 4.2.8 Prospect and Forecast
  • 4.3 Shanghai RAAS Blood Products Co., Ltd. (002252.SZ)
    • 4.3.1 Profile
    • 4.3.2 Operation
    • 4.3.3 Revenue Structure
    • 4.3.4 Gross Margin
    • 4.3.5 Customers and Suppliers
    • 4.3.6 R & D and Investment
    • 4.3.7 Prospect and Forecast
  • 4.4 Beijing Tiantan Biological Products Co., Ltd. (600161.SH)
    • 4.4.1 Profile
    • 4.4.2 Operation
    • 4.4.3 Revenue Structure
    • 4.4.4 Customers and Suppliers
    • 4.4.5 Gross Margin
    • 4.4.6 R & D and Investment
    • 4.4.7 Blood Products (Chengdu Rongsheng Pharmaceutical Co., Ltd.)
    • 4.4.8 Prospect and Forecast
  • 4.5 Zhenxing Biopharmaceutical and Chemical Co., Ltd. (000403.SZ)
    • 4.5.1 Profile
    • 4.5.2 Operation
    • 4.5.3 Revenue Structure
    • 4.5.4 Gross Margin
    • 4.5.5 Customers and Suppliers
    • 4.5.6 R & D and Investment
    • 4.5.7 Blood Products (Guangdong Shuanglin Bio-Pharmacy Co., Ltd.)
    • 4.5.8 Prospect and Forecast
  • 4.6 Jiangxi Boya Bio-Pharmaceutical Co., Ltd. (300294.SZ)
    • 4.6.1 Profile
    • 4.6.2 Operation
    • 4.6.3 Revenue Structure
    • 4.6.4 Gross Margin
    • 4.6.5 Customers and Suppliers
    • 4.6.6 R & D and Investment
    • 4.6.7 Prospect and Forecast
  • 4.7 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
    • 4.7.1 Profile
    • 4.7.2 Blood Products
  • 4.8 Shanghai Institute of Biological Products Co., Ltd.
    • 4.8.1 Profile
    • 4.8.2 Blood Products
  • 4.9 Shanxi Kangbao Biological Product Co., Ltd.
    • 4.9.1 Profile
    • 4.9.2 Blood Products
  • 4.10 Green Cross
    • 4.10.1 Profile
    • 4.10.2 Blood Products
  • 4.11 Humanwell Healthcare Group Co., Ltd. (600079.SH)
    • 4.11.1 Profile
    • 4.11.2 Operation
    • 4.11.3 Blood Products (Wuhan Zhongyuan Ruide Biological Product Co., Ltd.)
  • 4.12 Walvax Biotechnology Co, Ltd. (300142.SZ)
    • 4.12.1 Profile
    • 4.12.2 Operation
    • 4.12.3 Blood Products (Hebei Da'an Pharmaceutical Co., Ltd.)

5. Summary and Forecast

  • 5.1 Company Analysis
  • 5.2 Forecast

Selected Charts

  • Basic Composition of Blood
  • Plasma Protein Separation Procedure
  • Classification and Efficacy of Blood Products
  • Comparison between Gene Recombinant Blood Products and Traditional Blood Products
  • Comparison between Chinese and Overseas Recombinant Blood Products in Types
  • Blood Product Industry Chain
  • Time Length of Plasma Collection and Separation Process
  • Comparison between Blood Product Companies and Chemical & Pharmaceutical Enterprises in Operating Costs and Expenses
  • Prices of Some Blood Products in China, 2014
  • Chinese Blood Product Market Size, 2003-2014
  • Lot Release Volume of Blood Products in China (by Product), 2008-2014
  • Blood Product Structure in China (by Lot Release Volume), 2009-2014
  • Annual Production-use Plasma Volume in China, 2002-2014
  • Geographical Distribution of Plasma Collection Stations in China by the End of 2014
  • Main Blood Products with Medical Insurance Coverage in China
  • Comparison between China and Developed Countries in Per Capita Consumption of Blood Products
  • Plasma Station Distribution, Production-use Plasma Volume and Blood Product Revenue of Major Blood Product Manufacturers in China, 2014
  • Product Line Comparison between Blood Product Manufacturers in China
  • Competitive Landscape of Global Blood Product Enterprises, 2013
  • Product Structure of Global Blood Products
  • Blood Products Available in Foreign Countries
  • Global Blood Product Manufacturers
  • Major Policies on Blood Products in China
  • Policies on Maximum Retail Prices of Drugs in China, 2014
  • Lot Release Volume of Imported Human Albumin in China, 2008-2014
  • Average Human Albumin Purchase Price of Sample Hospitals in China, 2005-2014
  • Ratio of Domestically-produced to Imported Human Albumin in China (by Lot Release Volume), 2007-2014
  • Market Share of Major Human Albumin Manufacturers in China (by Lot Release Volume), 2008-2014
  • Consumption of Human Immunoglobulin (pH4) for Intravenous Injection Per 1,000 People by Country, 2013
  • Average Human Albumin Purchase Price of Sample Hospitals in China, 2005-2014
  • Lot Release Volume and Growth Rate of Human Immunoglobulin (pH4) for Intravenous Injection in China, 2007-2014
  • Price Comparison between Chinese and Overseas Human Immunoglobulin (pH4) for Intravenous Injection
  • Market Share of Major Manufacturers of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Lot Release Volume), 2007-2014
  • Lot Release Volume and Growth Rate of Blood Coagulation Factor VIII in China, 2008-2014
  • Market Share of Major Human Blood Coagulation Factor VIII Manufacturers in China (by Lot Release Volume), 2008-2014
  • Comparison between Human Blood Coagulation Factor VIII and Recombinant Blood Coagulation Factor VIII
  • Per Capita Consumption of Recombinant VIII Factor and Plasma VIII Factor in Major Countries
  • Lot Release Volume and Growth Rate of Hepatitis B Immunoglobulin in China, 2009-2014
  • Market Share of Major Hepatitis B Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2014
  • Prices of Human Immunoglobulin in China by Dosage, 2014
  • Lot Release Volume and Growth Rate of Human Immunoglobulin in China, 2008-2014
  • Market Share of Major Human Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2014
  • Lot Release Volume and Growth Rate of Human Prothrombin Complex in China, 2008-2014
  • Market Share of Major Human Prothrombin Complex Manufacturers in China (by Lot Release Volume), 2008-2014
  • Lot Release Volume and Growth Rate of Tetanus Immunoglobulin in China, 2008-2014
  • Market Share of Major Tetanus Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2014
  • Lot Release Volume and Growth Rate of Human Rabies Immunoglobulin in China, 2008-2014
  • Market Share of Major Human Rabies Immunoglobulin Manufacturers in China (by Lot Release Volume), 2008-2014
  • Equity Structure of China Biologic Products by the End of 2014
  • Distribution of Blood Product Production Bases and Plasma Stations of China Biologic Products, 2014
  • Revenue and Operating Income of China Biologic Products, 2007-2014
  • Gross Margin of China Biologic Products, 2011-2014
  • Revenue of China Biologic Products by Product, 2011-2014
  • Revenue Structure of China Biologic Products by Product, 2010-2014
  • Revenue of China Biologic Products from Top 5 Customers and % of Total Revenue, 2008-2014
  • R&D Costs and % of Total Revenue of China Biologic Products, 2010-2014
  • New Products of China Biologic Products under Research by the End of 2014
  • Lot Release Volume of Blood Products of Shandong Taibang, 2008-2014
  • Lot Release Volume of Blood Products of Guiyang Qianfeng, 2008-2014
  • Lot Release Volume of Blood Products of Xi'an Huitian Blood Products, 2008-2014
  • Revenue and Operating Income of China Biologic Products, 2014-2018E
  • Revenue and Operating Income of Hualan Biological, 2007-2014
  • Revenue of Hualan Biological by Sector, 2007-2014
  • Gross Margin of Hualan Biological by Product, 2007-2014
  • Revenue of Hualan Biological from Top 5 Customers and % of Total Revenue, 2007-2014
  • Procurement of Hualan Biological from Top Five Suppliers and % of Total Procurement, 2007-2014
  • Name List and Procurement of Hualan Biological's Top 5 Suppliers, 2014
  • R&D Costs and % of Total Revenue of Hualan Biological, 2007-2014
  • Varieties and Specifications of Blood Products of Hualan Biological
  • Plasma Collection Station Distribution of Hualan Biological by the End of 2014
  • Lot Release Volume of Blood Products of Hualan Biological, 2008-2014
  • Revenue and Gross Margin of Blood Products of Hualan Biological, 2007-2014
  • Revenue and Gross Margin of Hualan Biological by Product, 2007-2014
  • Revenue and Operating Income of Hualan Biological, 2014-2018E
  • Distribution of Plasma Collection Stations of Shanghai RAAS by the End of 2014
  • Revenue and Operating Income of Shanghai RAAS, 2008-2014
  • Lot Release Volume of Blood Products of Shanghai RAAS, 2008-2014
  • Lot Release Volume of TONROL's Blood Products, 2008-2014
  • Operating Revenue of Shanghai RAAS by Product, 2008-2014
  • Revenue of Shanghai RAAS by Region, 2008-2014
  • Gross Margin of Shanghai RAAS by Product, 2008-2014
  • Revenue of Shanghai RAAS from Top 5 Customers and % of Total Revenue, 2007-2014
  • Procurement of Shanghai RAAS from Top 5 Suppliers and % of Total Procurement, 2007-2014
  • R&D Costs and % of Total Revenue of Shanghai RAAS, 2007-2014
  • Revenue and Operating Income of Shanghai RAAS, 2014-2018E
  • Revenue and Profit of Tiantan Biological's Subsidiaries, 2014
  • Revenue and Operating Income of Tiantan Biological, 2007-2014
  • Revenue of Tiantan Biological by Sector, 2007-2014
  • Revenue of Tiantan Biological by Region, 2007-2014
  • Procurement of Tiantan Biological from Top 5 Suppliers and % of Total Procurement, 2008-2014
  • Revenue of Tiantan Biological from Top 5 Customers and % of Total Revenue, 2008-2014
  • Gross Margin of Tiantan Biological by Sector, 2008-2014
  • R&D Costs and % of Total Revenue of Tiantan Biological, 2009-2014
  • Distribution of Blood Plasma Collection Stations of Tiantan Biological by the End of 2014
  • Revenue and Gross Margin of Blood Products of Tiantan Biological, 2007-2014
  • Lot Release Volume of Blood Products of Chengdu Rongsheng and Tiantan Biological, 2008-2013
  • Revenue and Operating Income of Tiantan Biological, 2014-2018E
  • Revenue and Operating Income of Zhenxing Biopharmaceutical and Chemical, 2008-2014
  • Operating Revenue of Zhenxing Biopharmaceutical and Chemical by Product, 2009-2014
  • Gross Margin of Zhenxing Biopharmaceutical and Chemical by Product, 2009-2014
  • Revenue of Zhenxing Biopharmaceutical and Chemical from Top 5 Customers and % of Total Revenue, 2009-2014
  • Procurement of Zhenxing Biopharmaceutical and Chemical from Top 5 Suppliers and % of Total Procurement, 2013
  • R&D Costs and % of Total Revenue of Zhenxing Biopharmaceutical and Chemical, 2009-2014
  • Production-use Plasma Volume of Shuanglin Bio-Pharmacy, 2010-2014
  • Distribution of Plasma Collection Stations of Shuanglin Bio-Pharmacy by Jun 2014
  • Lot Release Volume of Blood Products of Shuanglin Bio-Pharmacy, 2008-2014
  • Revenue and Gross Margin of Blood Products Business of Zhenxing Biopharmaceutical and Chemical, 2009-2014
  • Revenue and Operating Income of Zhenxing Biopharmaceutical and Chemical, 2014-2018E
  • Plasma Collection Volume of Jiangxi Boya Bio-Pharmaceutical, 2008-2014
  • Revenue and Operating Income of Jiangxi Boya Bio-Pharmaceutical, 2008-2014
  • Revenue of Jiangxi Boya Bio-Pharmaceutical by Product, 2009-2014
  • Lot Release Volume of Main Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2011-2014
  • Operating Revenue of Jiangxi Boya Bio-Pharmaceutical by Region, 2009-2014
  • Gross Margin of Jiangxi Boya Bio-Pharmaceutical by Product, 2009-2014
  • Revenue of Jiangxi Boya Bio-Pharmaceutical from Top 5 Customers and % of Total Revenue, 2009-2013
  • Name List and Revenue Contribution of Top 5 Customers of Jiangxi Boya Bio-Pharmaceutical, 2014
  • Procurement of Jiangxi Boya Bio-Pharmaceutical from Top 5 Suppliers and % of Total Procurement, 2009-2014
  • R&D Costs and % of Total Revenue of Jiangxi Boya Bio-Pharmaceutical, 2009-2014
  • Revenue and Operating Income of Jiangxi Boya Bio-Pharmaceutical, 2014-2018E
  • Distribution of Blood Plasma Collection Stations of Yuanda Shuyang by the End of 2014
  • Lot Release Volume of Blood Products of Yuanda Shuyang, 2008-2014
  • Lot Release Volume of Blood Products of CNBG Shanghai Institute of Biological Products, 2008-2014
  • Distribution of Blood Plasma Collection Stations of CNBG Shanghai Institute of Biological Products by the End of 2014
  • Distribution of Blood Plasma Collection Stations of Shanxi Kangbao Biological Product by the End of 2014
  • Lot Release Volume of Blood Products of Shanxi Kangbao Biological Product, 2008-2014
  • Distribution of Blood Plasma Collection Stations of Green Cross China by the End of 2014
  • Lot Release Volume of Blood Products of Green Cross China, 2008-2014
  • Revenue and Operating Income of Humanwell Healthcare (Group), 2009-2014
  • Lot Release Volume of Blood Products of Wuhan Zhongyuan Ruide Biological Product, 2008-2014
  • Production Industry Layout of Walvax Biotechnology
  • Revenue and Operating Income of Walvax Biotechnology, 2009-2014
  • Revenue of Walvax Biotechnology by Sector, 2009-2014
  • Distribution of Plasma Stations of Major Blood Products Manufacturers in China by Dec 2014
  • Production-use Plasma Volume of Major Blood Product Manufacturers in China, 2014
  • Blood Product Revenue of Major Blood Product Manufacturers in China, 2011-2014
  • Main M & A Cases in China Blood Product Industry, 2008-2014
  • Chinese Blood Product Market Size, 2013-2018E
  • Gross Margin of Major Blood Products Manufacturers in China, 2011-2014
Show More
Pricing
Back to Top